Five AI tools to spot prostate cancer backed for NHS use
NICE has backed temporary NHS use of five AI tools that can help detect prostate cancer on MRI scans, while more evidence on their value is gathered.
Newsletters and Deep Dive digital magazine
NICE has backed temporary NHS use of five AI tools that can help detect prostate cancer on MRI scans, while more evidence on their value is gathered.
AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.
US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
GSK's antisense-based drug for chronic hepatitis B virus (HBV) infection, Hibsago, has been approved in the US, its second major market after Japan.
For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.
Editor's Picks
Newsletters and Deep Dive
digital magazine